Absstract of: WO2021189226A1

A method of taking a skin sample can include placing an adhesive onto a portion of skin and lifting the adhesive from the skin. A skin sample may then be tested while still on the adhesive, for example, by inoculating the sample with a bacterium, fungus, virus, or a combination.

Absstract of: US2022372116A1

The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contraception. The methods may be used to trap or separate particles and other substances. The subject matter further relates to methods of identifying and preparing optimal crosslinkers and methods for manipulating targets of interest.

Absstract of: WO2022241579A1

The invention relates to an antibacterial formulation comprising a mixture of bacteriophages that have lytic activity against Salmonella spp. strains, and a carrier, pH stabiliser and/or pharmaceutically and veterinarily acceptable excipients. This formulation is useful for the prevention and treatment of infectious diseases caused by Salmonella spp. and different serovars. The invention also relates to a use and method for preventing or treating infectious diseases caused by Salmonella spp. in breeding animals which comprises orally administering the antibacterial formulation to a non-human animal.

Absstract of: WO2021144254A1

The present invention relates to a Salmonella typhi Ty21a strain comprising a DNA molecule comprising at least one eukaryotic expression cassette encoding at least one tumor antigen, stroma antigen and/or checkpoint inhibitor antigen for the use in the treatment of cancer in a human subject following treatment with an antibiotic, wherein the Salmonella typhi Ty21a strain is to be administered orally and optionally in combination with a checkpoint inhibitor.

Absstract of: EP3378485A1

The present invention relates to bacteriocins for control of Salmonella enterica (salmocins). The bacteriocins are derived from Salmonella. The salmocins can be expressed in plants and can be used in a method of preventing or reducing infection or contamination of an object with Salmonella.

Absstract of: CN115350274A

本发明属于药物制剂领域，涉及一种长度可控的鞭毛纳米纤维的制备及其作为黏膜佐剂的应用。该制剂以菌体分离出的鞭毛纤维作为黏膜佐剂，采用探头超声技术实现对纤维长度的调控。通过体外细胞实验，证明了鞭毛纳米纤维在不造成细胞毒性的前提下，能诱导先天免疫细胞TLR5的活化，以及线粒体活性氧的产生，并进一步鉴定NLRP3和NLRC4炎性体可以被该制剂活化，阐明了细胞因子IL‑1β的产生机制。通过体内动物实验，进一步证明对鞭毛纳米纤维佐剂长度的调控可以实现对黏膜免疫反应的调控，并证明了长度是鞭毛蛋白纳米纤维穿透黏液层的关键因素。同时，鞭毛蛋白纳米纤维通过黏膜免疫的方式可促进细胞免疫的产生，并发挥抗肿瘤功效。

Absstract of: AU2021265090A1

In a general aspect, microorganisms [e.g., bacteria, etc.) are identified and detected. In some examples, a liquid solvent is supplied through a first channel of a sampling probe to an internal reservoir of the sampling probe; a fixed volume of the liquid solvent in the internal reservoir is held in direct contact with a sample surface for a period of time to form a liquid analyte; gas is supplied to the internal reservoir through a second channel of the sampling probe; the liquid analyte is extracted from the internal reservoir through a third channel of the sampling probe; the liquid analyte is transferred to a mass spectrometer; the mass spectrometer processes the liquid analyte to produce mass spectrometry data; and the mass spectrometry data are analyzed to detect and identify a microorganism [e.g., bacteria, fungi, or another type of microorganism) present at the sample surface.

Absstract of: CN115340997A

本发明公开一种基于Lpp引导序列靶向呈递和高效表达外源抗原的重组沙门菌构建方法，利用同源重组方法将大肠杆菌Lpp引导序列引入到本实验室前期构建的pS‑SaoA质粒中，形成重组表达质粒pS‑Lpp‑SaoA，在猪霍乱沙门菌载体菌株rSC0016中引入pS‑Lpp‑SaoA质粒，形成重组猪霍乱沙门菌rSC0016（pS‑Lpp‑SaoA）；外源抗原SaoA在该菌株及其OMVs中可以高效表达和靶向呈递，免疫小鼠后可产生强大的体液免疫和细胞免疫，并产生高水平的细胞因子，保护小鼠免受猪链球菌致死剂量的攻击；本发明为无佐剂OMVs疫苗平台提供了一种有前景的通用策略，具有较大的市场应用潜力和潜在的经济效益。

Absstract of: WO2018106754A1

A method of treating cancer includes administering a dose of a chemotherapy agent in combination with a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent. The combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the composition consisting essentially of attenuated Salmonella typhimurium.

Absstract of: US2022354919A1

An extract of an herbal composition comprising at least two different dried plants useful as antimicrobial and/or antibiofilm agent in the treatment or prevention of microbial infections caused by bacteria, such as for example Escherichia, Klebsiella, Listeria, Pseudomonas, Salmonella, Streptococcus or Staphylococcus, or by fungi, such as for example is herein described. It has been found that in such extract, the active ingredients exert their biological effects in a synergistic manner. The extract may constitute the active ingredient of a food supplement, a nutraceutical, pharmaceutical or cosmetic composition or a functional food or a food additive. A process for preparing said extract is also described here.

Absstract of: AU2021235152A1

The invention relates to an enriched population of modified lipopolysaccharide (LPS) molecular species being: - devoid of phosphate group at position C1 of the reducing end of their lipid A domain; and - substituted at position C6' of the non-reducing end of their lipid A domain by a hydrophilic moiety, with the proviso that said hydrophilic moiety is not a hydroxyl group. It also relates to compositions comprising the enriched population of modified LPS; and uses of naturally-occurring LPS molecular species and/or enriched population of modified LPS molecular species for treating and/or preventing cancer, inflammatory diseases or infectious diseases, and for stimulating an immune response or vaccinating a subject.

Absstract of: AU2021250442A1

The present invention relates to a DNA vaccine comprising a

Absstract of: KR20220149313A

본 발명은 약독화 살모넬라 갈리나룸 균주 및 이의 용도에 관한 것이다. 구체적으로, 구아노신 4인산 (Guanosine tetraphosphate, ppGpp) 합성효소를 암호화하는 유전자, type III 분비 시스템 (type III secretion system, T3SS)의 기능을 유도하는 유전자 (ssrAB), 및 Gifsy 2 prophage 유전자가 모두 결실된 신규한 약독화 살모넬라 균주, 및 이를 이용한 종양 치료 또는 진단용 조성물에 관한 것이다.

Absstract of: WO2021044436A2

The present disclosure relates to novel immunogenic monovalent and multivalent polysaccharide-protein conjugate vaccine compositions comprising a polysaccharide selected from Salmonella serovar strains S. typhi; S. paratyphi A; S. typhimurium and S. enteritidis and alternative improved methods of polysaccharide fermentation, polysaccharide purification, polysaccharide-protein conjugation and stable formulation. The present disclosure further relates to methods for inducing an immune response in subjects against Salmonella typhi and non-typhi related diseases and/or for reducing or preventing Salmonella typhi and non-typhi related diseases in subjects using the compositions disclosed herein. The vaccine elicits bactericidal antibodies and is useful for prevention of gastroenteritis, enteric and typhoid fever.

Absstract of: US2022347295A1

A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

Absstract of: WO2022231043A1

The present invention relates to an attenuated Salmonella gallinarum strain and use thereof. Particularly, the present invention relates to: a novel attenuated Salmonella strain in which all of a gene encoding guanosine tetraphosphate (ppGpp) synthetase, a gene that induces the function of a type III secretion system (T3SS)(ssrAB), and a Gifsy 2prophage gene are deleted; and a composition for treating or diagnosing tumors by using same.

Absstract of: EP4080216A1

The present invention relates to an in vitro method for testing a drug for the treatment of bacterial infections, wherein the method is characterized by determining the potential of the drug to inhibit binding of type I piliated gram-negative bacteria to CD14.The present invention also relates to a CD14 antibody for use in the treatment of urinary tract infections as well as a combination of a CD14 antibody with antibiotics, mannose and/or mannoside. The present invention also relates to a CD14 antibody for use in the treatment of persistent and/or recurrent urinary tract infections.

Absstract of: US2022332770A1

The invention provides a novel fusion protein between flagellin (or portions thereof) and a polypeptide that can form a virus-like particle (VLP) (e.g., hepatitis b core (HBc) protein or portions thereof), where the fusion protein continues to form a VLP in an aqueous environment. The VLPs based on such fusion proteins (e.g., FH VLPs) provide a versatile, highly immunogenic, and safe vaccine carrier capable of displaying or associating a variety of vaccine antigens on VLP surface to elicit potent humoral and cellular immune responses.

Absstract of: WO2022217031A1

Formaldehyde is a common component of antimicrobial compositions for preserving animal feeds. However, the use of formaldehyde is coming under pressure and alternative antimicrobial compositions are needed. The present application discloses methods and/or uses of a formaldehyde-free antimicrobial composition comprising formic acid and propionic acid in the making of rendered animal protein compositions or in the inhibiting of the development of Salmonella bacteria in animal by-product compositions (e.g., rendered animal proteins) while maintaining higher protein digestibility comparing with formaldehyde.

Absstract of: US2022323562A1

Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.

Absstract of: AU2021224585A1

The present disclosure provides immunogenic compositions comprising Group A Streptococcus (GAS) polypeptide antigens and at least one polypeptide-polysaccharide conjugate. The present disclosure further provides methods of using such compositions to induce immune responses against GAS infections in subjects.

Absstract of: WO2022216731A1

Provided are modified bacteria and methods of using the modified bacteria for prophylaxis or treatment of bacterial infections. The modified bacteria contain one or more genomic modifications such that the genomes of the bacteria are altered to encode and produce a holin protein and to encode and produce a lysozyme. The modified bacteria are illustrated using a type of Salmonella enterica (SE) in the form of autolytic SE serovar Typhimurium (S. Typhimurium).

Absstract of: WO2021167996A1

The present disclosure provides immunogenic compositions comprising Group A Streptococcus (GAS) polypeptide antigens and at least one polypeptide-polysaccharide conjugate. The present disclosure further provides methods of using such compositions to induce immune responses against GAS infections in subjects.

Absstract of: WO2021167996A1

The present disclosure provides immunogenic compositions comprising Group A Streptococcus (GAS) polypeptide antigens and at least one polypeptide-polysaccharide conjugate. The present disclosure further provides methods of using such compositions to induce immune responses against GAS infections in subjects.

Absstract of: WO2021020923A1

The present invention relates to a composition for preventing, alleviating, or treating liver injury, for example, non-alcoholic fatty liver and, more particularly, to a composition comprising a Ruminococcus sp. strain for preventing or treating liver injury.